The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

AbbVie and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets ...

Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

Here is a selection of people starting new roles with Waterways Ireland, IOB, Eaton, AbbVie Ireland, Deloitte Ireland and ...

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

AbbVie will receive royalties on net sales within Greater China. Credit: © AbbVie Inc. All rights reserved. AbbVie and Simcere Zaiming have announced an option-to ...